Can TP53, TMB and TME Expand the Immunotherapy Benefit in Metastatic Colorectal Cancer?
Monia Specchia, Denise Drittone, Eva Mazzotti, Federica Mazzuca · 2025
Read Can TP53, TMB and TME Expand the Immunotherapy Benefit in Metastatic Colorectal Cancer? by Monia Specchia, Denise Drittone, Eva Mazzotti, Federica Mazzuca (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12731181.txt.
Description
Monia Specchia, Denise Drittone, Eva Mazzotti, and Federica Mazzuca wrote this review, published in 2025. It asks whether immunotherapy, now a star for one slice of bowel cancer, can help the harder majority. The focus is metastatic colorectal cancer carrying TP53 mutations, a group with aggressive disease and poor outcomes.
Drugs that release the immune system work well when a tumor's DNA repair is faulty, but most bowel cancers lack that trait. The review gathers trial and lab evidence on waking the immune system in these stubborn tumors. Pairing the drugs with chemotherapy, DNA-damage agents, or blood vessel normalizers shows early promise, above all when mutation load runs high. The authors argue that reading TP53 status, mutation load, and the tumor's surroundings together could widen who benefits. They call for first-line trials built on that logic.
Catalog record
| CREATOR | Monia Specchia, Denise Drittone, Eva Mazzotti, Federica Mazzuca |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |